Indication of Echocardiographic Investigation in the Neonatal period: Value of Risk Groups. 1028

Sadeck, Lílian S. R.; Calil, Valdenise Martins Laurindo Tuma; Azevedo, Renato Ferreira Leitão; Barbato, Alfonso; Latorre, M.R.O.; Rebello, Celso Moura; Leone, Cléa Rodrigues; Ramos, José Lauro Araújo

doi:10.1203/00006450-199704001-01047

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of neonatal CHD is approximately 8%, with a perinatal mortality rate as high as 40% and mortality rate as high as 20% in the first month following birth [3]. Fetal mortality rates included deaths from pulmonary hypertension, bacterial endocarditis and congestive heart failure, although complex CHD was the main cause of early death [4].…”

Section: Circulating Lncrnas As Novel Noninvasive Biomarkers For Prementioning

confidence: 99%

Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects

Zheng

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Objectives: To explore the clinical value of circulating long non-coding RNAs (lncRNAs) as biomarkers to predict fetal congenital heart defects (CHD) in pregnant women. Methods: Differential expression of lncRNAs isolated from the plasma of pregnant women with typical fetal CHD or healthy controls was analyzed by microarray. Gene ontology (GO), pathway and network analysis were performed to study the function of the lncRNAs. Differentially expressed lncRNAs were validated in plasma samples from 62 pregnant women with typical CHD and 62 matched controls by RT-PCR. The sensitivity and specificity of each lncRNA in the diagnosis of fetal CHD was determined by ROC curve analysis. Results: Microarray analysis identified 3694 up-regulated and 3919 down-regulated (fold change ≥2.0) lncRNAs. The top ten significantly differentially expressed, CHD-associated lncRNAs were validated by RT-PCR. Five significantly up-regulated or down-regulated lncRNAs were identified: ENST00000436681, ENST00000422826, AA584040, AA709223 and BX478947 with the AUC of ROC curves calculated as 0.892, 0.817, 0.755, 0.882 and 0.886, respectively. Conclusions: Specific lncRNAs aberrantly expressed in the plasma of pregnant women with typical fetal CHD may play a key role in the development of CHD and may be used as novel biomarkers for prenatal diagnosis of fetal CHD.

show abstract

Section: Circulating Lncrnas As Novel Noninvasive Biomarkers For Prementioning

confidence: 99%

Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects

Zheng

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

Indication of Echocardiographic Investigation in the Neonatal period: Value of Risk Groups. 1028

Cited by 1 publication

References 0 publications

Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects

Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects

Contact Info

Product

Resources

About